c-MET (G1163R)

MET · Variant type: point · HGVS: p.G1163R

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Tepotinib	91.8%	8.2%	99.75
2	Capmatinib	91.8%	8.2%	99.75
3	Repotrectinib	68.9%	31.1%	84.21
4	Deucravacitinib	59.2%	40.8%	98.99
5	Erdafitinib	32.0%	68.0%	95.71
6	Defactinib	28.9%	71.1%	92.68
7	Tivozanib	28.0%	72.0%	92.42
8	Ripretinib	11.0%	89.0%	92.95
9	Palbociclib	9.5%	90.5%	98.75
10	Canertinib	9.5%	90.5%	96.49
11	Selpercatinib	9.0%	91.0%	96.72
12	Erlotinib	8.9%	91.1%	99.75
13	Sunitinib	7.6%	92.4%	91.73
14	Neratinib	7.0%	93.0%	93.18
15	Capivasertib	5.9%	94.1%	96.48
16	Abemaciclib	5.5%	94.5%	91.48
17	Infigratinib	5.5%	94.5%	98.24
18	Vandetanib	5.0%	95.0%	95.74
19	Gilteritinib	4.7%	95.3%	88.97
20	Umbralisib	4.6%	95.4%	98.74
21	Avapritinib	4.4%	95.6%	97.73
22	Upadacitinib	4.3%	95.7%	97.98
23	Apatinib	3.7%	96.3%	97.73
24	Selumetinib	3.3%	96.7%	100.00
25	Leniolisib	3.2%	96.8%	100.00

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Tepotinib	91.8%	—	—
Capmatinib	91.8%	—	—
Repotrectinib	68.9%	—	—
Deucravacitinib	59.2%	—	—
Erdafitinib	32.0%	—	—
Defactinib	28.9%	—	—
Tivozanib	28.0%	—	—
Ripretinib	11.0%	—	—
Palbociclib	9.5%	—	—
Canertinib	9.5%	—	—
Selpercatinib	9.0%	—	—
Erlotinib	8.9%	—	—
Sunitinib	7.6%	—	—
Neratinib	7.0%	—	—
Capivasertib	5.9%	—	—
Abemaciclib	5.5%	—	—
Infigratinib	5.5%	—	—
Vandetanib	5.0%	—	—
Gilteritinib	4.7%	—	—
Umbralisib	4.6%	—	—
Avapritinib	4.4%	—	—
Upadacitinib	4.3%	—	—
Apatinib	3.7%	—	—
Selumetinib	3.3%	—	—
Leniolisib	3.2%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms